A Phase II Two-Arm Open-Label Study of Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression
Phase of Trial: Phase II
Latest Information Update: 30 Jan 2019
Price : $35 *
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Relatlimab (Primary)
- Indications Malignant melanoma
- Focus Biomarker; Therapeutic Use
- 18 Jan 2019 Status changed from not yet recruiting to recruiting.
- 04 Jan 2019 Planned End Date changed from 1 Dec 2023 to 1 Feb 2024.
- 04 Jan 2019 Planned primary completion date changed from 1 Dec 2022 to 1 Feb 2023.